Background and Purpose-Early prediction of clinical outcome after aneurysmal subarachnoid hemorrhage (aSAH) is still lacking accuracy. In this observational cohort study, we aimed to develop and validate an accurate bedside prediction model for clinical outcome after aSAH, to aid decision-making at an early stage. Methods-For the development of the prediction model, a prospectively kept single-center cohort of 1215 aSAH patients, admitted between 1998 and 2014, was used. For temporal validation, a prospective cohort of 224 consecutive aSAH patients from the same center, admitted between 2015 and 2017, was used. External validation was performed using the ISAT (International Subarachnoid Aneurysm Trial) database (2143 patients). Primary outcome measure was poor functional outcome 2 months after aSAH, defined as modified Rankin Scale score 4-6. The model was constructed using multivariate regression analyses. Performance of the model was examined in terms of discrimination and calibration.
S
pontaneous aneurysmal subarachnoid hemorrhage (aSAH) is a severe type of hemorrhagic stroke with a mortality rate up to 35%. Approximately one-third of the survivors remain severely disabled and functionally dependent. 1 Early and reliable prediction of the patients' outcome after SAH is important in clinical practice for decision-making about treatment options but also for providing information for the patients and their families. Despite the development of multiple grading scales, their clinical usefulness is limited, mostly because of lack of accuracy and generalizability. [2] [3] [4] Recently, Jaja et al 5 developed multiple prediction models for outcome after aneurysmal SAH. However, the use of these multiple models is confusing and the inclusion of poorly definable variables, such as hypertension, make the clinical applicability questionable.
Clinical decisions are nowadays largely based on the initial neurological condition of the patient using the World Federation of Neurosurgical Societies (WFNS) SAH grading scale (Table I in the online-only Data Supplement). 6 However, the use of the WFNS grade alone leads to overly pessimistic prognoses, especially in poor-grade patients. 7 Recently, it has been shown that the WFNS score assessed after neurological resuscitation (rWFNS; eg, cerebral spinal fluid drainage for acute hydrocephalus or evacuation of an intracerebral hematoma) is a significant better predictor for outcome compared with the initial WFNS score. 8, 9 Although several other variables have been identified as predictor for clinical outcome, these have not all been confirmed in other studies and are not all available at an early stage. 4, [10] [11] [12] [13] [14] [15] Our objective was to develop and validate a bedside prediction model for clinical outcome after aSAH, using a prospectively kept cohort for temporal validation as well as data from the ISAT (International Subarachnoid Aneurysm Trial) database for external validation.
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Methods

Derivation Cohort
The data that support the findings of this study are available from the corresponding author on reasonable request. For the development of the prediction model, data from our prospectively maintained observational cohort were used, including 1620 SAH patients admitted to our university neurovascular center between January 1998 and December 2014. The treatment protocol and methods were published before. 8 According to our treatment protocol, withdrawal of care (including life-support) in patients with an infaust prognosis within 72 hours after the ictus was only permitted after neurosurgical resuscitation. An infaust prognosis refers to a state where a patient will inevitably die, for example, when diagnosed as brain dead.
For the development of this model we only included aSAH patients, excluding 384 patients with non-aSAH or intracranial dissection. Also, we excluded 21 patients who died before computed tomography angiography or digital subtraction angiograph could be performed to identify an aneurysm. As a result, 1215 patients were considered eligible for inclusion. Ethics approval was obtained from our local institutional review board. In addition, given the observational design of our study, the board waived the need for patient consent.
Temporal Validation Cohort
Temporal validation was performed using the prospectively kept cohort of 224 aSAH patients admitted to the University Medical Center Groningen between January 2015 and December 2017.
External Validation Cohort
For external validation, the ISAT data set was used. ISAT was a randomized controlled trial comparing the safety and efficacy of endovascular coiling versus neurosurgical clipping. The data set includes 2143 patients with aSAH, recruited between 1994 and 2002 in 43 international centers. ISAT included only patients considered eligible for both treatment modalities; patients who died before randomization were not included. In the ISAT cohort, the WFNS grade was prospectively collected at time of randomization. As in ISAT, the median time between ictus and randomization was 2 days, it is likely that live-saving neurological resuscitation is performed before randomization. 16 Therefore, the WFNS at time of randomization in ISAT is considered the equivalent of the rWFNS.
Outcome Measures
The primary outcome measure was poor functional outcome 2 months after SAH according to the modified Rankin Scale (mRS). 17 Poor outcome was defined as an mRS of 4, 5, or death (6) ( Table II in the online-only Data Supplement). In all cohorts, the mRS score was assessed by a questionnaire during standardized outpatient follow-up visits.
Model Development
The following variables were prospectively collected in the derivation cohort: date of ictus, age at time of SAH, sex, history of SAH, hypertension, rWFNS grade, symptomatic aneurysm size and location, amount of blood on initial computed tomographic scan, acute hydrocephalus requiring initiation of cerebrospinal fluid drainage within 24 hours after ictus, type and time of aneurysm repair, and early rebleeding. If it was not possible to identify the symptomatic aneurysm because of multiple aneurysms (n=22), the largest aneurysm was selected for analysis. Hypertension was defined as a systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg or controlled using antihypertensive drugs. Age of the patient and the location and the size of the symptomatic aneurysm were classified according to the PHASES study. 18 As shown previously, the WFNS grade assessed after neurological resuscitation is a better predictor for clinical outcome compared with the WFNS assessed on admission. 8 As initial poor-grade patients can significantly improve after neurological resuscitation, only the truly poor-grade patients remain in this category. Therefore, the rWFNS grade was included in the model development. For validation purposes, the Fisher scale was used instead of the modified Fisher scale to classify the amount of blood on the computed tomographic scan (Table III in the online-only Data Supplement). As a sensitivity analysis, we analyzed the model performance in the derivation cohort, using the mFisher scale. A rebleeding of the ruptured aneurysm was defined as a sudden clinical deterioration with a concomitant increase of subarachnoid, intracerebral, or intraventricular blood on the subsequent computed tomographic scan or when similar signs and symptoms occurred without computed tomography confirmation.
Univariate logistic regression analysis was performed after which all variables with a P<0.15 were included in the multivariate logistic regression analysis. Backwards stepwise selection was applied to obtain the best predictive model, a cutoff point of P<0.10 was used for inclusion in the final model. 19 Results are presented as odds ratios with 95% CI. Bootstrapping with 100 replacement samples was performed to validate the model internally. Since data are collected over a relatively long period of time, and clinical outcome of SAH patients has improved significantly in recent years, 20 additional sensitivity analyses were performed in 3 consecutive timeframes (1998-2003, 2004-2009, and 2010-2014) .
Model Performance
Model performance was assessed in terms of discrimination and calibration. Discrimination of the model is the ability to distinguish between patients with a poor versus good outcome and was examined using the area under the receiver operating characteristic (ROC) curve (AUC) with corresponding 95% CI. Calibration of the model is the ability to predict the actual outcome in patients and was examined using likelihood-ratio tests and visualized with calibration belt graphs. 21 Model performance was compared with the nowadays used WFNS grading scale and the recently developed SAHIT prediction models.
Risk Chart
The contribution of each covariate for poor outcome was calculated by conversion of the final regression β coefficients to a nominal value, after which for each score the sum scores of the predictive covariates were calculated in the derivation cohort. These sum scores where then compared with the predicted probability for poor outcome of each case, after which a risk chart for poor outcome was constructed.
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Missing Data
In the derivation cohort, data were missing for aneurysm size (16%), Fisher grade (7%), and outcome (3%). Multiple imputations (10 data sets) with multivariate regression analysis was used to impute these missing variables. Complete case analysis was performed as sensitivity analysis. In the temporal validation cohort, aneurysm size and location were unknown for 2 patients (1%) because of death before computed tomography angiography or digital subtraction angiograph. Furthermore, the mRS score for 5 patients was missing because of loss of follow-up. In the ISAT cohort, the mRS score at 2 months after aSAH was missing for 15 patients. For 8 of these patients, mRS scores at a later time are known, which were used to impute for the missing mRS after 2 months. In the end, outcome was considered unknown for 7 patients (1%). Because the percentage of missing data in both validation cohorts is statistically negligible, 19 complete case analyses were used in the validation process. A 2-tailed P value of <0.05 was considered to indicate statistical significance. Statistical analyses were performed using SPSS version 24.0 (SPSS Inc) and STATA version 15.0 (StataCorp, College Station, TX).
Results
Patients Characteristics of the Derivation Cohort
The distribution of the patients' characteristics and prognostic factors for the derivation cohort are shown in Table 1 . The majority of the patients were female (67%), and median age was 55 years (interquartile range, 46-65). Most aneurysms were located in the anterior circulation (42%). Poor outcome after 2 months was observed in 28% of the patients (Table 2 ). In 90 patients (7%), the prognosis was determined infaust within the first 24 hours, after which life-support was withdrawn, leading to death.
Model Development
Results of the logistic regression are presented in Table 3 . Age, rWFNS grade, aneurysm size, and Fisher grade were independent predictors for poor outcome. Internal validation and complete case analysis showed no bias (Table IV in 
Model Validation
The baseline patient characteristics for both validation cohorts are shown in Table 1 . Median age was 58 years (interquartile range, 50-67) in the temporal validation cohort and 52 years (interquartile range, 44-60) in the ISAT validation cohort. The ISAT cohort included patients with smaller aneurysms, which were more often located in the anterior region. Furthermore, ISAT clearly had a smaller proportion of patients with an rWFNS of 4 and 5. Poor outcome after 2 months was observed in 36% of the patients in the temporal validation cohort and in 17% of the ISAT cohort (Table 2) In temporal validation, there was agreement between expected and observed poor outcome. A similar result was seen in external validation, with a slight underestimation of the observed poor outcome in the low-risk patients (Figure [C] ). For the highrisk patients, there was agreement between expected and observed poor outcome.
Comparison With Other Prediction Models
As a comparison, discriminative performance of the currently used WFNS scale is calculated for all cohorts and is shown in Figure IVA through IVC in the online-only Data Supplement. In all cohorts, the AUC of the WFNS scale is considerably lower compared with our model. Discriminative performance of the neuroimaging model of SAHIT in our cohort was comparable to our developed model ( Figure V in the online-only Data Supplement). Table 4 shows the SAFIRE risk chart: Size of the aneurysm, age, Fisher grade, WFNS after resuscitation, based on the β coefficients derived from the regression analyses. After the calculation of the sum score, the corresponding SAFIRE grade can be derived from the grading scale (Table 5 ). The regression equation with the β coefficients and corresponding intercept (constant) is provided in Results in the online-only Data Supplement.
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Discussion
We aimed to develop a model for prediction of outcome after aSAH. We identified 4 easily obtainable variables at presentation to be independently associated with poor outcome after 2 months: age, rWFNS grade, aneurysm size, and Fisher grade. The model showed good discriminative performance and model fit, also in both validation cohorts. Together, these 4 variables were used to develop the SAFIRE grading scale.
To be considered clinically useful, prediction models need to include clinically relevant parameters which are easy and early to obtain. More importantly, the model needs accuracy and generalizability, which can only be obtained after external validation. 23 In contrast to published prognostic models, where external validation is lacking, 2 this model has been externally validated, showing satisfactory accuracy and generalizability. When compared with the still widely used WFNS scale, the current model discriminates considerably better.
The observational nature of the derivation cohort contributes to the generalizability of our model, because all patients with aSAH are included, and thus no selection bias exists, while most other prediction models are developed on trial data. 14, 24, 25 Trials in general include select patient populations and may, therefore, not always be suitable for development of prediction models. In contrast, for external validation, clinical trial data are very useful, although performance is often poorer compared with cohort data. 5, 24, 25 This selection bias often observed in clinical trials may explain the lower discriminative performance of the SAFIRE grading scale in the ISAT cohort.
Another explanation for the relatively lower performance of the model in the ISAT cohort may be the use of relatively outdated data. The last ISAT patients were recruited in 2002, and over the past decades treatment and outcome of patients with aSAH has significantly improved. 20, 26 Besides improvement in diagnostic modalities and treatment techniques, a shift in treatment modality used to treat aneurysms has occurred. In the past, the large majority of aneurysms were treated with neurosurgical clipping, whereas nowadays ≈80% are secured via endovascular coiling. The same phenomenon is also observed within the derivation cohort. Although our model is developed on the basis of a cohort collected over a significant time span, the discrimination in the more recent timeframe ( Figure IIC 
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Comparison With Other Prediction Models
Risselada et al 25 developed in 2010 a prognostic model for mortality alone after aSAH, based on the ISAT cohort. This model yielded an AUC of 0.73. However, when tested externally in another selected group of aSAH patients by Dijkland et al, 3 the model did not fit well. Moreover, the use of mortality as the sole end point for the prediction model, which is also used in the SAHIT study, 5 is clinically less useful when compared with poor clinical outcome.
Recently, Blessings et al developed multiple prediction models for outcome after aSAH, based on the SAHIT dataset. (24) 101 (31) 257 (12) Early rebleeding (<72 h) 77 (7) 35 (11) 50 (2) (10) 17 (8) 341 (16) 40-49 y 295 (24) 31 (14) 539 (25) 50-59 y 350 (29) 76 (34) 719 (34) 60-69 y 269 (22) 50 (22) 408 (19) >70 y 176 (15) 50 (22) 136 (6) History Previous SAH 26 (2) 10 (4) The SAHIT prediction model is comparable to SAFIRE in performance, but the latter is easier to use as a bedside grading model. We created one prediction model, instead of 6, with only 4 well-defined variables. Furthermore, the inclusion of the predictor hypertension in the SAHIT models is debatable, as it is poorly defined. Some variables associated with poor outcome, such as laboratory parameters or variables, obtained in a later stage in the 
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aSAH course, such as treatment or delayed cerebral ischemia, were not included in our model. 5, [11] [12] [13] Although the inclusion of these variables may slightly improve the prognostic value, it is important to consider we aimed to develop a prediction model to aid decision-making at an early stage before actual treatment.
Strengths and Limitations
Some limitations of the study need to be addressed. First, 2 of the predictors in our model, aneurysm size and Fisher grade, are sensitive for measurement errors. Because ISAT contains multicenter data of these variables, similar measurement errors exist in this cohort. Hence, the good external validation suggests that this does not affect the reliability of the model. Second, complications in the course after aSAH, such as rebleeding of the aneurysm or delayed cerebral ischemia, are not included in the model but can influence the outcome significantly. 6 Third, for validation purposes, the Fisher scale was used instead of the mFisher scale. Nowadays, the mFisher scale is preferred because the grades are better defined, and it is more accurate in the prediction of delayed cerebral ischemia. However, the mFisher has not been proven to be more accurate in prediction of outcome as such. In addition, in our model, the performance of both scales is comparable. Fourth, the rWFNS score was not collected in ISAT. Because the WFNS score in ISAT was determined after averagely 2 days, we considered this WFNS score as equivalent of the rWFNS score. It is, however, important to note that this it is only an approximation, performed for validation purposes. Last, it is important to consider that patients who died because of withdrawal of life-support in case of an infaust prognosis are also included in this model. The decision to stop life-support because of an infaust prognosis can be considered a self-fulfilling prophecy to some extent and as such may contribute to confounding in prediction models. 27 Ideally, a prediction model is developed in a population in which no patients are withdrawn of care, which is unfortunately rare in clinical practice.
There are several strengths of this study. First, the cohort used for model development is one of the largest unselected observational cohorts of aSAH patients available. Second, the identified predictors are all easy obtainable at an early stage, which makes this model useful as a bedside predictive scale. Most importantly, the model shows accuracy in both temporal and external validation, outperforms currently used models including the WFNS, and can, therefore, be considered widely applicable. 
Clinical Implications
For physicians, reliable prediction of clinical outcome in aSAH patients soon after admission is of utmost importance for decision-making about treatment. In clinical practice, aneurysm repair is sometimes delayed or withheld because treatment is seen as futile, whereas the patient actually has a reasonable chance of a good outcome. This is, recently shown by Goldberg et al, 28 especially the case in elderly patients with low WFNS grades (IV and V). In this study, Goldberg et al 28 showed that these patients can have favorable outcomes when maximal treatment is given. The SAFIRE grading scale is more accurate compared with the nowadays used WFNS grading scale, of which it is known that 20% of the poor WFNS grade patients recover without any neurological deficits. 7 Withholding aneurysm repair is keeping these patients unnecessary at risk for aneurysm rebleeding. 29 Because of the SAFIRE grading scale especially identifies poor-grade patients more accurately, it can help physicians with difficult decisions about treatment for these patients.
The importance of accurate identification of true poorgrade patients is also illustrated by some current questions about type and timing of aneurysm repair in these patients. It is known that in good-grade patients, coiling is favorable over clipping, but for poor-grade patients firm evidence is lacking. 30 Also, it is unclear whether poor-grade patients benefit from early treatment (<24 hours after ictus), which is nowadays more often standard for good-grade patients. 31 The SAFIRE grading scale can aid with better identification of poor-grade patients and can thus be used in future trials about these subjects. Hopefully, this will lead to better treatment of these patients in clinical practice.
Besides WFNS grading scale, other developed prediction models are rarely used not only because of lack of accuracy but also lack of ease to use. The SAFIRE grading scale excels in simplicity and can be used by all physicians involved in the treatment of aSAH patients. In future research, we encourage further validation of the grading scale, to establish an optimal prediction model with broad support throughout the neurovascular community.
Conclusions
The SAFIRE grading scale is an accurate, generalizable, and easily applicable model for early prediction of clinical outcome after aSAH. The bedside grading scale identifies poor-grade patients better compared with the nowadays used WFNS score and can, therefore, aid decision-making about treatment at an early stage. 
